Fermi America™ and ASP Isotopes Join Forces to Secure America's Advanced Reactor Fuel Supply
AMARILLO, Texas, Aug. 15, 2025 /PRNewswire/ — Fermi America, developer of the 11 GW private grid campus for next-generation hyperscale AI in collaboration with the Texas Tech University System, today announced it has signed a Memorandum of Understanding (MOU) with ASP Isotopes Inc. (NASDAQ: ASPI) and its subsidiary Quantum Leap Energy LLC (QLE) to explore the development of a High Assay Low Enriched Uranium (HALEU) enrichment facility at Fermi America's site in Carson County, Texas.
The planned facility would use advanced laser-based isotope separation technology to produce HALEU — a specialized nuclear fuel essential for many Generation IV and small modular reactor (SMR) designs. With very few commercial HALEU suppliers currently operating in the Western world, the project is intended to strengthen U.S. and allied supply chains, reduce reliance on Russian enrichment, and accelerate the deployment of advanced nuclear technologies.
Fermi America's private grid campus will be anchored by four AP1000® nuclear units using conventional fuel, with the potential to integrate advanced reactor technologies in future phases. The addition of domestic HALEU production capability would position the private grid as both a significant clean energy generator and a strategic nuclear fuel hub. 'Our nation's ability to lead in advanced nuclear energy is directly tied to our capacity to fuel it here at home,' said Toby Neugebauer, Co-Founder and CEO, Fermi America. 'This decision helps ensure that America's next generation of nuclear reactors will be powered by American innovation, technology, and resolve.'
'This collaboration represents a decisive step toward securing the nuclear fuel needed for the next wave of advanced reactors,' said Mesut Uzman, Chief Nuclear Construction Officer, Fermi America. 'It reinforces our mission to build the most advanced, resilient, and secure private grid in the world.'
'Advanced reactors cannot be built without HALEU, and our Quantum Enrichment™ technology is designed to deliver it with speed, precision, and environmental responsibility,' said Paul Mann, Chairman and CEO, ASP Isotopes Inc. 'Partnering with Fermi America gives us the platform and location to play a central role in the emerging Western HALEU market.'
'Energy security is national security,' said Rick Perry, Co-Founder of Fermi America and former U.S. Secretary of Energy. 'This project will help America control its own destiny in nuclear power, create jobs here in Texas, and send a clear message that the United States intends to lead – not follow – in the race for advanced, carbon-free energy.'
According to the U.S. Department of Energy, U.S. HALEU demand could exceed 50 metric tons annually by 2035, with similar needs emerging in Europe and Asia. The proposed project would help meet this demand, supporting the clean energy transition while enhancing energy security.
For media inquiries, please contact:Lexi Swearingen[email protected]
About Fermi America Fermi America is pioneering the development of next-generation electric grids that deliver highly redundant power at gigawatt scale, essential for enabling next-generation artificial intelligence. Co-founded by former U.S. Energy Secretary Rick Perry, Fermi America's behind-the-meter HyperGrid campus will integrate the largest nuclear power complex in America, the nation's biggest combined-cycle natural gas project, utility grid power, solar power, and battery energy storage.
About the Texas Tech University SystemEstablished in 1996, the Texas Tech University System is one of the top public university systems in the nation, consisting of five universities – Texas Tech University, Texas Tech University Health Sciences Center, Angelo State University, Texas Tech University Health Sciences Center El Paso and Midwestern State University.
Headquartered in Lubbock, Texas, the TTU System is a more than $3 billion enterprise focused on advancing higher education, health care, research and outreach with approximately 21,000 employees and 64,000 students, more than 400,000 alums, a statewide economic impact of $19.2 billion and an endowment valued at $3 billion. In its short history, the TTU System has grown tremendously and is nationally acclaimed, operating at 20 academic locations in 16 cities (15 in Texas, 1 international).
In addition, the TTU System is one of only nine in the nation to offer programs for undergraduate, medical, law, nursing, pharmacy, dental and veterinary education, among other academic areas.
About ASP Isotopes Inc.ASP Isotopes Inc. (NASDAQ: ASPI) is an advanced materials company dedicated to the production of enriched isotopes for use in multiple industries, including nuclear energy, medicine, semiconductors, and quantum computing. Through its subsidiary Quantum Leap Energy, ASPI is developing Quantum Enrichment™ technology to produce HALEU fuel and other critical isotopes at lower cost, faster, and with no radioactive waste.
Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, future operations, financial position, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements because they contain words such as 'may,' 'will,' 'will be,' 'will likely result,' 'should,' 'expects,' 'plans,' 'anticipates,' 'could,' 'would,' 'foresees,' 'intends,' 'target,' 'projects,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'outlook,' or 'continue' or the negative of these words or other similar terms or expressions. These forward-looking statements are not guarantees of future performance, but are based on management's current expectations, assumptions, and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. Our results could be materially different from our expectations because of various risks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
Dow ends higher, other indices slip on rate-cut uncertainty
The Dow rose 34.86 points, or 0.08%, to 44,946.12, the S&P 500 lost 18.74 points, or 0.29%, to 6,449.80 and the Nasdaq lost 87.69 points, or 0.40%, to 21,622.98. NEW YORK: The blue-chip Dow Jones ended higher after hitting an intraday record high on Friday, as UnitedHealth's shares jumped after Berkshire Hathaway raised its stake, but other Wall Street indices slipped as mixed data clouded the Federal Reserve's next monetary policy move. A meeting between US President Donald Trump and Russian counterpart Vladimir Putin was also on the radar, with markets hoping it could pave the way for a resolution to the Ukraine conflict and determine the outlook for crude prices. The two leaders began a meeting in Alaska on Friday afternoon.
The Star
4 hours ago
- The Star
Europe's born-again bonds
FIFTEEN years ago, Guillermo Felices was helping clients navigate Europe's sovereign debt crisis. Now, he's extolling the bonds once at the centre of that storm. Italy, Spain, Ireland, Portugal and Greece, which nearly collapsed under the burden of their debt in 2011, have since transformed into top picks for firms like PGIM Fixed Income, where Felices works as a London-based investment strategist.
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression
Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ — Researchers from Children's Hospital of Philadelphia (CHOP) and Children's Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during childhood leads to less stiffening of the esophagus, resulting in fewer disease complications. Using Endoluminal functional imaging (FLIP), the study team suggests this could be a key marker for assessing disease severity and progression. The findings were published online today by the journal Gastroenterology. EoE is a chronic allergic inflammatory disease of the esophagus, the muscular tube that carries food from the throat to the stomach. Children can experience nausea, regurgitation, vomiting, abdominal pain and a burning feeling like acid reflux. They may also have difficulty swallowing and gag frequently. Often, they can experience dysphagia, which is when it feels like something is stuck in their throat. If EoE goes untreated, the esophagus may narrow because of scarring, a phenomenon known as stricture. Chronic EoE-associated inflammation can lead to progressive tissue remodeling and fibrostenosis, or the narrowing of the esophagus. While clinicians recognize the severity of the disease, long-term studies looking at disease progression over time, and the impact of controlling the disease from a young age, is relatively unknown. 'This is the first study to follow kids overtime (with these endoscopic assessments) and evaluate the patients who are at the highest risk of complications,' said co-senior study author Amanda Muir, MD, a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at CHOP. 'With the recent FDA approval of two medications for EoE, having this data could help identify the patients who could benefit from these therapies the most and observe improvement at a histologic level over time.' Researchers at CHOP and Children's Hospital Colorado launched a longitudinal study to evaluate long-term changes in esophageal distensibility, or the ability of the esophagus to expand, in pediatric patients between the ages of 3 and 18 years old. Symptomatic, endoscopic and histologic data were collected at each visit during the study. A total of 112 patients with EoE were included with a median follow-up time of 11 months, some followed for over 4 years. 'Following children living with EoE over time has given us a clearer picture of how inflammation affects the esophagus and how treating it can improve the esophagus and outcomes for patients,' said Calies Menard-Katcher, MD, co-senior study author and Associate Director of Clinical Research for the Gastrointestinal Eosinophilic Diseases Program at Children's Hospital Colorado. 'It's exciting to see these results confirm what we've suspected in caring for patients — and they may even help us spot those at risk for more severe disease.' The study found that patients with tissue samples showing a response to treatment demonstrated the most improvement in distensibility over time. After adjusting for different factors, the study found that patients with lower esophageal distensibility had increased odds of patient-reported dysphagia, or difficulty swallowing. Patients with fibrostenosis were generally diagnosed at an older age, had the disease for a longer period and showed reduced esophageal distensibility at baseline predicted the need for future dilation in patients with strictures. The authors suggest that further studies that examine the disease from a molecular level could help them understand which patients may be at highest risk of severe disease and could benefit from a variety of treatment strategies. This study was supported by the National Institutes of Health grants R01DK124266-01, K23DK109263 and R21TR003039. Kennedy et al, 'Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis.' Gastroenterology. Online August 15, 2025. DOI: 10.1053/ About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit ABOUT CHILDREN'S HOSPITAL COLORADO Children's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Contact: Ben LeachChildren's Hospital of Philadelphia(609)634-7906leachb@
